Get The Best Care for Your Chronic Lymphocytic Leukemia (CLL)
The CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on
patient education, support, and research. Dedicated to addressing the unmet needs of the Chronic Lymphocytic Leukemia (CLL) community,
our goal is to provide real, recent and relevant information and to be the “go to place” for CLL patients and caregivers.
What’s New in CLL?
PI3K inhibitors have been largely neglected in CLL due to the tremendous success of ibrutinib, a BTK inhibitor. Both classes of drugs block the B cell receptor and are very effective in controlling CLL, but the side effects are different. At ASH 2018, Dr. Davids shares the latest encouraging research on duvelisib.
Too often outcomes in the real world, especially far away from academic centers are not as good as they are in trials. Dr. Roeker at ASH 2018 shares that the real world outcomes with venetoclax were similar to those found in the clinical studies. This is also important as Dr. Roeker is part of a new generation of young CLL researchers that we patients need to support and encourage. Read more details on this promising news and Dr. Koffman’s commentary here.
- Having undetectable CLL in your blood or bone marrow is increasingly a realistic possibility. When and how it is important is the topic of my discussion with Dr. Wierda at ASH 2018.